IsisCB Explore

Article ID: CBB001320753

“The Strophanthin Question”: Early Scientific Marketing of Cardiac Drugs in Two National Markets (France and Germany, 1900--1930). (2013)

History and Technology
Volume: 29, no. 2
Issue: 2
Pages: 135-152

Publication Date: 2013
Edition Details: Part of a special issue on the 20th century marketing and advertising of pharmaceuticals.
Language: English

Outside Links

WorldCat

Google Scholar

JSTOR

Academia.edu

Pharmaceutical industry Advertising Marketing techniques Research and development (R&D) Therapeutic practice; therapy; treatment Chemical drugs Cardiovascular disease Physicians; doctors 20th century, early Germany France

Historical analyses of marketing strategies in pharmaceutical companies have focused disproportionately on `big-pharma' corporations. This paper explores scientific marketing at the `ordinary' level of a minor pharmaceutical -- called Strophanthin in Germany and Ouabaine in France -- used for treating cardiac problems. The narrative offers a comparative German-French perspective but will emphasize the early twentieth century activities of a German, middle-sized, family-run pharmaceutical company, Boehringer Mannheim. The case highlights the existence of a pre-1940 nexus of corporate-professional relations that contrasts with the analytic narratives of the extant literature, which primarily gives attention to that small number of corporations whose operations have spanned the earlier and later decades of the twentieth century and to their approaches to industrial R&D and marketing. Here the focus is on the marketing practices of a middle-sized firm, which deployed a strategy of marketing different than their larger competitors, including their approach to national and international market sales. In this context, a `physician-push model' of marketing was pre-eminent, in which individual physicians, such as Albert Fraenkel in the Strophanthin case, played a central role not only in researching and developing a drug but also in its promotion. Looking at `scientific marketing' as a form of promotion that was part of a transnational peer-to-peer network, the paper concludes that significant differences existed between France and Germany in their style of advertising in professional journals. [ABSTRACT FROM PUBLISHER]

...More

Included in

Article Gaudillière, Jean-Paul; Thoms, Ulrike (2013) Pharmaceutical Firms and the Construction of Drug Markets: From Branding to Scientific Marketing. History and Technology (pp. 105-115). unapi

Citation URI

https://data.isiscb.org/isis/citation/CBB001320753/

Citations Indexes

Similar Citations

Article Thoms, Ulrike; (2013)
Standardizing Selling. Pharmaceutical Marketing, the Pharmaceutical Company and the Marketing Expert (1900--1980) (/isis/citation/CBB001320755/)

Article Hüntelmann, Axel C.; (2013)
A Different Mode of Marketing? The Importance of Scientific Articles in the Marketing Process of Salvarsan (/isis/citation/CBB001320752/)

Article Gaudillière, Jean-Paul; (2013)
From Propaganda to Scientific Marketing: Schering, Cortisone, and the Construction of Drug Markets (/isis/citation/CBB001320756/)

Book Sara E. Black; (2022)
Drugging France: Mind-Altering Medicine in the Long Nineteenth Century (/isis/citation/CBB100452937/)

Chapter Gaudillière, Jean-Paul; (2008)
Professional and Industrial Drug Regulation in France and Germany: The Trajectories of Plant and Gland Extracts before 1945 (/isis/citation/CBB001221035/)

Book Jones, Claire; (2013)
The Medical Trade Catalogue in Britain, 1870--1914 (/isis/citation/CBB001202367/)

Article Katrin Amelang; Susanne Bauer; (August 2019)
Following the algorithm: How epidemiological risk-scores do accountability (/isis/citation/CBB077353059/)

Article Joris Mercelis; (2020)
The scientist and the advertisement: Reklamegutachten in imperial Germany (/isis/citation/CBB621920403/)

Article Bonnemain, Bruno; (2007)
La publicité pharmaceutique et parapharmaceutique des Annales vertes en 1927 (/isis/citation/CBB000933378/)

Article Gaudillière, Jean-Paul; Thoms, Ulrike; (2013)
Pharmaceutical Firms and the Construction of Drug Markets: From Branding to Scientific Marketing (/isis/citation/CBB001320751/)

Article Quirke, Viviane; (2006)
Putting Theory into Practice: James Black, Receptor Theory and the Development of the Beta-Blockers at ICI, 1958--1978 (/isis/citation/CBB000773951/)

Article Anna Greenwood; Hilary Ingram; (2018)
‘The People’s Chemists’: The Walgreens Boots Alliance Archive (/isis/citation/CBB146301261/)

Article Quirke, Viviane; (2014)
Targeting the American Market for Medicines, ca. 1950s–1970s: ICI and Rhône-Poulenc Compared (/isis/citation/CBB001202354/)

Article Greene, Jeremy A.; (2011)
What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine (/isis/citation/CBB001230383/)

Article Sá, Ivone Manzali de; (2011)
A resistência à cloroquina e a busca de antimalariais entre as décadas de 1960 e 1980 (/isis/citation/CBB001420522/)

Article Hersch Martínez, Paul; García Poujol, Miguel; (2008)
La flora como recurso terapéutico: el caso de los extractos fluidos de Laboratorios Codex en México (/isis/citation/CBB000931737/)

Article Podolsky, Scott H.; Greene, Jeremy A.; (2009)
Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America (/isis/citation/CBB000932130/)

Article Bonnemain, Bruno; (2008)
Le médecin vu par les documents publicitaires de l'industrie pharmaceutique du XXème siècle (/isis/citation/CBB000933269/)

Article Kessel, Nils; (2013)
“Doriden von Ciba: Sleeping Pills, Pharmaceutical Marketing, and Thalidomide, 1955--1963 (/isis/citation/CBB001320754/)

Article Ilenia Garoia; (2017)
Farmacista, preparatore, comunicatore, innovatore: il caso Oreste Ruggeri (1857-1912) (/isis/citation/CBB233428609/)

Comments

{{ comment.created_by.username }} on {{ comment.created_on | date:'medium' }}